Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
Holding HIMS?
Track your performance easily
HIMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.40 - $30.44
Previous Close$19.32
Volume32.41M
Average Volume (3M)12.65M
Market Cap
$4.22B
Enterprise Value$3.98B
Total Cash (Recent Filing)$254.07M
Total Debt (Recent Filing)$11.36M
Price to Earnings (P/E)44.7
Beta2.40
Next Earnings
Mar 03, 2025EPS Estimate
$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding218,479,114
10 Day Avg. Volume29,894,721
30 Day Avg. Volume12,648,243
Standard Deviation0.20
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.61
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)13.40
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit5.56
Enterprise Value/Ebitda33.33
Forecast
1Y Price Target
$24.00Price Target Upside24.22% Upside
Rating ConsensusHold
Number of Analyst Covering12
Hims & Hers Health News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHims & Hers' 3Q results exceeded expectations even after estimates were raised comfortably above consensus.
Personalization And GrowthPersonalization is resonating with patients underpinning robust core business growth.
Subscriber And Revenue GrowthThe core business continues to show strong adoption rates with 3Q subscriber growth increasing 40% year-over-year.
Bears Say
CompetitionAmazon's entrance into these markets signals growing competition for customers and is expected to impact the prices that HIMS can charge, HIMS' ability to grow and capture new customers, and HIMS' LTV/CAC.
Regulatory UncertaintyThe FDA reviewing its decision to remove tirzepatide from the shortage list shows that the question of potential duration for HIMS' compounded GLP-1s sales, and the inherent uncertainties around supply shortages, will remain in focus and continue to cause stock volatility.
Revenue DurabilityThere is uncertainty around the longer-term opportunity for HIMS to benefit from compounded semaglutide, with concerns about the durability of the business post-shortage persisting.
---
Ownership Overview
10.47% Insiders
16.35% Mutual Funds
12.41% Other Institutional Investors
37.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $7.40 and its highest was $30.44 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Mar 03, 2025 which is in 107 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Nov 04, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.111 by $0.209.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is $0.18.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 210,101,490 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.32 in its last earnings report, beating expectations of $0.111. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Royce & Associates LLC. It holds Hims & Hers Health’s shares valued at 6M.
---
Hims & Hers Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.00 (24.22% Upside)
$24.00 (24.22% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 84%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 21.4%
Last 30 Days ▲ 21.4%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.58%
12-Months-Change
Fundamentals
Return on Equity
26.35%
Trailing 12-Months
Asset Growth
45.52%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
HIMS Earnings Call
Q3 2024
0:00 / 0:00
---
HIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
---
HIMS Stock 12 Month Forecast
Average Price Target
$24.00
▲(24.22% Upside)
Technical Analysis
Best Analysts Covering HIMS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+119.79%
assigned a buy rating 9 days ago
Copying Jonna Kim's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +119.79% per trade.
---